Kamalini G Ranasinghe1, Katherine P Rankin2, Iryna V Lobach1, Joel H Kramer1, Virginia E Sturm1, Brianne M Bettcher1, Katherine Possin1, S Christine You1, Amanda K Lamarre1, Tal Shany-Ur1, Melanie L Stephens1, David C Perry1, Suzee E Lee1, Zachary A Miller1, Maria L Gorno-Tempini1, Howard J Rosen1, Adam Boxer1, William W Seeley1, Gil D Rabinovici1, Keith A Vossel1, Bruce L Miller1. 1. From the Memory and Aging Center (K.G.R., K.P.R., I.V.L., J.H.K., V.E.S., B.M.B., K.P., S.C.Y., A.K.L., T.S.-U., M.L.S., D.C.P., S.E.L., Z.A.M., M.L.G.-T., H.J.R., A.B., W.W.S., G.D.R., K.A.V., B.L.M.), Department of Neurology, University of California, San Francisco; Departments of Neurosurgery and Neurology (B.M.B.), University of Colorado Anschutz School of Medicine, Aurora; and Gladstone Institute of Neurological Disease (K.A.V.), CA. 2. From the Memory and Aging Center (K.G.R., K.P.R., I.V.L., J.H.K., V.E.S., B.M.B., K.P., S.C.Y., A.K.L., T.S.-U., M.L.S., D.C.P., S.E.L., Z.A.M., M.L.G.-T., H.J.R., A.B., W.W.S., G.D.R., K.A.V., B.L.M.), Department of Neurology, University of California, San Francisco; Departments of Neurosurgery and Neurology (B.M.B.), University of Colorado Anschutz School of Medicine, Aurora; and Gladstone Institute of Neurological Disease (K.A.V.), CA. krankin@memory.ucsf.edu.
Abstract
OBJECTIVE: To characterize the cognitive and neuropsychiatric symptoms of patients with behavioral variant frontotemporal dementia (bvFTD) over the natural course of the disease. METHODS: We examined the initial and subsequent neuropsychological test performance and neuropsychiatric symptoms in a large cohort of patients with bvFTD (n = 204) across progressive stages of disease as measured by the Clinical Dementia Rating (CDR). We also compared cognitive and neuropsychiatric impairments of patients with bvFTD to those of an age-matched cohort with Alzheimer disease (AD) dementia (n = 674). RESULTS: At the earliest stage (CDR = 0.5), patients with bvFTD had profound neuropsychiatric disturbances, insensitivity to errors, slower response times, and poor naming, with intact attention span, memory, and facial affect naming. Tests continuing to show progressive, statistically significant stepwise declines after the CDR = 1 stage included free recall, visuoconstruction, set-shifting, error insensitivity, semantic fluency, design fluency, emotion naming, calculations, confrontation naming, syntax comprehension, and verbal agility. At CDR = 0.5, patients with bvFTD significantly outperformed patients with AD in episodic memory and were faster in set-shifting, while scoring quantitatively worse in lexical fluency, emotion naming, and error sensitivity. The overall rate of disease progression in bvFTD was more rapid than in AD. CONCLUSION: There are distinct patterns of cognitive deficits differentiating the earlier and later disease stages in bvFTD, with the pattern of cognitive decline revealing in greater detail the natural history of the disease. These cognitive symptoms are readily apparent clinical markers of dysfunction in the principal brain networks known to undergo molecular and anatomical changes in bvFTD, thus are important indicators of the evolving pathology in individual patients.
OBJECTIVE: To characterize the cognitive and neuropsychiatric symptoms of patients with behavioral variant frontotemporal dementia (bvFTD) over the natural course of the disease. METHODS: We examined the initial and subsequent neuropsychological test performance and neuropsychiatric symptoms in a large cohort of patients with bvFTD (n = 204) across progressive stages of disease as measured by the Clinical Dementia Rating (CDR). We also compared cognitive and neuropsychiatric impairments of patients with bvFTD to those of an age-matched cohort with Alzheimer disease (AD) dementia (n = 674). RESULTS: At the earliest stage (CDR = 0.5), patients with bvFTD had profound neuropsychiatric disturbances, insensitivity to errors, slower response times, and poor naming, with intact attention span, memory, and facial affect naming. Tests continuing to show progressive, statistically significant stepwise declines after the CDR = 1 stage included free recall, visuoconstruction, set-shifting, error insensitivity, semantic fluency, design fluency, emotion naming, calculations, confrontation naming, syntax comprehension, and verbal agility. At CDR = 0.5, patients with bvFTD significantly outperformed patients with AD in episodic memory and were faster in set-shifting, while scoring quantitatively worse in lexical fluency, emotion naming, and error sensitivity. The overall rate of disease progression in bvFTD was more rapid than in AD. CONCLUSION: There are distinct patterns of cognitive deficits differentiating the earlier and later disease stages in bvFTD, with the pattern of cognitive decline revealing in greater detail the natural history of the disease. These cognitive symptoms are readily apparent clinical markers of dysfunction in the principal brain networks known to undergo molecular and anatomical changes in bvFTD, thus are important indicators of the evolving pathology in individual patients.
Authors: Joel H Kramer; Jennifer Jurik; Sharon J Sha; Kate P Rankin; Howard J Rosen; Julene K Johnson; Bruce L Miller Journal: Cogn Behav Neurol Date: 2003-12 Impact factor: 1.600
Authors: Jennifer L Whitwell; Valerie M Anderson; Rachael I Scahill; Martin N Rossor; Nick C Fox Journal: Dement Geriatr Cogn Disord Date: 2004 Impact factor: 2.959
Authors: Mary K Floeter; Bryan J Traynor; Jennifer Farren; Laura E Braun; Michael Tierney; Edythe A Wiggs; Tianxia Wu Journal: Neurology Date: 2017-06-14 Impact factor: 9.910
Authors: Maxime Bertoux; Marie Sarazin; Florence Pasquier; Michel Bottlaender; Leonardo Cruz de Souza; Eneida Mioshi; Michael Hornberger; Kamalini G Ranasinghe; Katherine P Rankin; Iryna V Lobach; Joel H Kramer; Virginia E Sturm; Brianne M Bettcher; Katherine Possin; S Christine You; Amanda K Lamarre; Tal Shany-Ur; Melanie L Stephens; David C Perry; Suzee E Lee; Zachary A Miller; Maria L Gorno-Tempini; Howard J Rosen; Adam Boxer; William W Seeley; Gil D Rabinovici; Keith A Vossel; Bruce L Miller Journal: Neurology Date: 2016-10-04 Impact factor: 9.910
Authors: K B Casaletto; G Marx; S Dutt; J Neuhaus; R Saloner; L Kritikos; B Miller; J H Kramer Journal: Neuropsychologia Date: 2017-05-23 Impact factor: 3.139
Authors: Kamalini G Ranasinghe; Jungho Cha; Leonardo Iaccarino; Leighton B Hinkley; Alexander J Beagle; Julie Pham; William J Jagust; Bruce L Miller; Katherine P Rankin; Gil D Rabinovici; Keith A Vossel; Srikantan S Nagarajan Journal: Sci Transl Med Date: 2020-03-11 Impact factor: 17.956
Authors: Kamalini G Ranasinghe; Jeevit S Gill; Hardik Kothare; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Maria Luisa Gorno-Tempini; Bruce L Miller; Keith A Vossel; Srikantan S Nagarajan; John F Houde Journal: Neurobiol Aging Date: 2017-01-03 Impact factor: 4.673
Authors: Kamalini G Ranasinghe; Leighton B Hinkley; Alexander J Beagle; Danielle Mizuiri; Susanne M Honma; Ariane E Welch; Isabel Hubbard; Maria Luisa Mandelli; Zachary A Miller; Coleman Garrett; Alice La; Adam L Boxer; John F Houde; Bruce L Miller; Keith A Vossel; Maria Luisa Gorno-Tempini; Srikantan S Nagarajan Journal: Brain Date: 2017-10-01 Impact factor: 13.501